ArticleThe Journal of clinical endocrinology and metabolism2020
One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes.
Article in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06815081 (A Study to Determine a Capillary Alternative to the Gold Standard Oral Glucose Tolerance Test), which is not on this map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study to Determine a Capillary Alternative to the Gold Standard Oral Glucose Tolerance Test
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- UK best practice recommendations for children and young people <18 years with pre-stage 3 type 1 diabetes, on behalf of the British Society for Paediatric Endocrinology and Diabetes (BSPED).Diabetic medicine : a journal of the British Diabetic Association · 2025Guideline
- Testing methods used to predict disease progression in children with early-stage type 1 diabetes: A systematic review and meta-analysis.Diabetic medicine : a journal of the British Diabetic Association · 2025Pooled it
- ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes.Hormone research in paediatrics · 2024Guideline
- C-Peptide Provides Critical Contextual Insight Into Elevated Glucose Values During Progression to Type 1 Diabetes.Diabetes care · 2026Review
- Type 1 diabetes prediction in autoantibody-positive individuals: performance, time and money matter.Diabetologia · 2025Article
- Discrimination and Precision of Continuous Glucose Monitoring in Staging Children With Presymptomatic Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2025Article
- Review
- Early Dysglycemia Is Detectable Using Continuous Glucose Monitoring in Very Young Children at Risk of Type 1 Diabetes.Diabetes care · 2024Article
- Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes.Diabetologia · 2024Article
- Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes.Diabetes care · 2024Article
- Screening and Prevention of Type 1 Diabetes: Where Are We?The Journal of clinical endocrinology and metabolism · 2023Review
- Predictive Value of 1-Hour Glucose Elevations during Oral Glucose Tolerance Testing for Cystic Fibrosis-Related Diabetes.Pediatric diabetes · 2023Article
- The association of physical activity to oral glucose tolerance test outcomes in multiple autoantibody positive children: The TEDDY Study.Pediatric diabetes · 2022Article
- Continuous Glucose Monitoring Profiles in Healthy, Nondiabetic Young Children.Journal of the Endocrine Society · 2022Article
- Article
- Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.Diabetologia · 2021Article
- Pancreatic islet reserve in type 1 diabetes.Annals of the New York Academy of Sciences · 2021Review
- The 1-Hour Plasma Glucose: Common Link Across the Glycemic Spectrum.Frontiers in endocrinology · 2021Review
- The Oral Glucose Tolerance Test: 100 Years Later.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
contextOnce islet autoantibody-positive individuals are identified, predicting which individuals are at highest risk for type 1 diabetes (T1D) is important. A metabolic risk score derived from 2-hour oral glucose tolerance test (OGTT) data, the Diabetes Prevention Trial-Type 1 risk score (DPTRS), can accurately predict T1D. However, 2-hour OGTTs are time-consuming and costly.
objectiveWe aimed to determine whether a risk score derived from 1-hour OGTT data can predict T1D as accurately as the DPTRS. Secondarily, we evaluated whether a 1-hour glucose value can be used for diagnostic surveillance.
methodsThe DPTRS was modified to derive a 1-hour OGTT risk score (DPTRS60) using fasting C-peptide, 1-hour glucose and C-peptide, age, and body mass index. Areas under receiver operating curves (ROCAUCs) were used to compare prediction accuracies of DPTRS60 with DPTRS in Diabetes Prevention Trial-Type 1 (DPT-1) (n = 654) and TrialNet Pathway to Prevention (TNPTP) (n = 4610) participants. Negative predictive values (NPV) for T1D diagnosis were derived for 1-hour glucose thresholds.
resultsROCAUCs for T1D prediction 5 years from baseline were similar between DPTRS60 and DPTRS (DPT-1: 0.805 and 0.794; TNPTP: 0.832 and 0.847, respectively). DPTRS60 predicted T1D significantly better than 2-hour glucose (P < .001 in both cohorts). A 1-hour glucose of less than 180 mg/dL had a similar NPV, positive predictive value, and specificity for T1D development before the next 6-month visit as the standard 2-hour threshold of less than 140 mg/dL (both ≥ 98.5%).
conclusionA 1-hour OGTT can predict T1D as accurately as a 2-hour OGTT with minimal risk of missing a T1D diagnosis before the next visit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.